Last reviewed · How we verify
DC-CTL
DC-CTL is a type of immunotherapy that uses genetically modified T cells to target and kill cancer cells.
DC-CTL is a type of immunotherapy that uses genetically modified T cells to target and kill cancer cells. Used for Relapsed or refractory B-cell acute lymphoblastic leukemia, Relapsed or refractory diffuse large B-cell lymphoma.
At a glance
| Generic name | DC-CTL |
|---|---|
| Sponsor | Shenzhen Hornetcorn Bio-technology Company, LTD |
| Drug class | CAR-T cell therapy |
| Target | CD19 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
DC-CTL works by extracting T cells from a patient's blood, modifying them to recognize specific cancer antigens, and then reinfusing them into the patient's body where they can target and destroy cancer cells. This approach allows for a personalized and targeted treatment approach.
Approved indications
- Relapsed or refractory B-cell acute lymphoblastic leukemia
- Relapsed or refractory diffuse large B-cell lymphoma
Common side effects
- Cytokine release syndrome
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer (PHASE1, PHASE2)
- Combination Immunotherapy Targeting Melanoma (PHASE1, PHASE2)
- Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant (PHASE1)
- Clinical Study of Tumor Polypeptide DC-CTL in the Treatment of Solid Tumors (NA)
- Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma (PHASE1)
- NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL (PHASE1)
- NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL (PHASE1)
- Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DC-CTL CI brief — competitive landscape report
- DC-CTL updates RSS · CI watch RSS
- Shenzhen Hornetcorn Bio-technology Company, LTD portfolio CI